Some proteins hold down two unrelated jobs at once, and drugs that target one job can silently hit the other. NAT10 is a case in point, and in the heart its two jobs appear to pull in opposite directions. In one study, NAT10 overexpression in cardiomyocytes pushed adult heart-muscle cells back into the cell cycle and improved heart repair after injury — and it did this without its better-known enzymatic activity of depositing ac4C chemical marks on RNA, acting instead as a physical RNA-binding roadblock that shuts down translation of two mitochondrial genes, Uqcr11 and Uqcrb (N-Acetyltransferase 10 represses Uqcr11 and Uqcrb independently of ac4C modification to promote heart regeneration). In a second study, NAT10 in macrophages did require its ac4C catalytic activity to stabilize the mRNA of the inflammatory transcription factor Ets2, driving a cytokine storm that damaged the heart (Impact of N-acetyltransferase 10 on macrophage activation and inflammation-induced cardiac dysfunction). A small-molecule inhibitor of the catalytic site, Remodelin, is therefore attractive as a cardiac-protective anti-inflammatory drug — but nobody knows whether occupying that same catalytic pocket disturbs the non-catalytic, pro-regenerative scaffolding function that cardiomyocytes depend on.
This proposal does the experiment that resolves that question, and it goes one step further into the territory nobody has mapped: whether cardiomyocytes carrying a molecularly split version of NAT10 change what they tell their neighbors. Cardiac scarring is not just local fibroblast proliferation; it depends on fibroblasts migrating as a collective swarm, a behavior driven by N-cadherin upregulation and demonstrated in fascia with the SCAD explant system, where blocking N-cadherin with the Exherin peptide produced a roughly 65% reduction in N-cadherin expression and abolished swarming (Injury triggers fascia fibroblast collective cell migration to drive scar formation through N-cadherin). Whether cardiac fibroblasts swarm the same way after infarction, and whether a cardiomyocyte's internal metabolic state — cycling versus arrested — rewrites the paracrine signals that set fibroblast migration in motion, are both open questions with no answer in the literature.
Core Claim
The claim is that NAT10's catalytic (ac4C-writing) and non-catalytic (RNA-scaffolding) functions can be separated by knock-in point mutants, and that this separation produces different secretomes: a cardiomyocyte expressing catalytically dead NAT10 keeps the pro-regenerative metabolic reprogramming — repressed Uqcr11/Uqcrb, dampened mitochondrial complex III, restored glycolysis, cell-cycle re-entry — while releasing none of the ac4C-dependent pro-inflammatory messaging that a wild-type enzyme would amplify in immune cells. If that catalytic-dead secretome also restrains cardiac fibroblast collective migration in scratch and Transwell assays, then catalytic-dead NAT10 is simultaneously pro-regeneration and anti-fibrotic, and the field gains both a mechanistic answer and a screening platform for deciding whether Remodelin is safe for the regeneration side of the heart.
Research Program
The program has three modules. The first is the separation-of-function toolkit. Following the logic of catalytically dead mutants used elsewhere to isolate scaffolding from chemistry — hexokinase 2's nuclear stemness role separated from glycolysis (The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness) and UCK2's metastatic scaffolding separated from nucleotide phosphorylation (The Metabolic and Non-Metabolic Roles of UCK2 in Tumor Progression) — we will construct three alleles: wild-type NAT10, a catalytic-dead mutant with the acetyltransferase active site ablated, and an RNA-binding-dead mutant that preserves catalysis but loses Uqcr11/Uqcrb binding. These will be expressed in primary neonatal and adult mouse cardiomyocytes and in macrophages at matched stoichiometry, with stability and folding checked so that a phenotype cannot be blamed on misfolding — the known failure mode of this mutagenesis style.
The second module is the paracrine readout. Conditioned medium from each cardiomyocyte genotype will be transferred to cardiac fibroblast monolayers, and a scratch assay — a standardized wound scratched into a confluent cell sheet, filmed as the sheet closes — will measure collective migration, with mitomycin C added so that closure reflects movement rather than division, the standard confound flagged in the assay literature. Because NAT10 inhibits ferroptosis and promotes the progression of renal clear cell carcinoma by regulating the NFE2L1-GPX4 signaling pathway showed NAT10 accelerates scratch closure cell-autonomously in cancer cells, we will also run fibroblast-intrinsic NAT10 manipulations in monoculture as an ablation arm, so that any secretome effect can be distinguished from a fibroblast-internal NAT10 effect. The macrophage arm mirrors this: LPS-stimulated macrophages from the three alleles plus Remodelin treatment, conditioned media onto cardiomyocytes, measuring whether catalytic-dead NAT10 in macrophages acts as a dominant negative that blunts Ets2 stabilization and cytokine output, extending what Xiao et al. showed with total knockout and Remodelin.
The third module is the secretome itself. Rather than profiling blindly, we will use CellChat, a tool that infers ligand-receptor communication from single-cell RNA-seq using a database of roughly 2,021 curated interactions and that reduces false-positive links by about 10–14% versus single-pair inference, as triage on published infarct single-cell datasets (Inference and analysis of cell-cell communication using CellChat), then validate the top predicted cardiomyocyte-to-fibroblast and cardiomyocyte-to-macrophage axes by targeted proteomics on the actual conditioned media. This order matters because CellChat infers from mRNA abundance, while the whole NAT10 mechanism in Ma et al. operates at the level of ribosome occupancy with mRNA unchanged — the exact case where transcriptomic proxies fail. For any candidate mediator whose mRNA NAT10 might directly acetylate, we can consult PACES, a random-forest predictor of ac4C sites reporting an area under the ROC curve of 0.8741 on an independent test set (PACES: prediction of N4-acetylcytidine (ac4C) modification sites in mRNA), though its area under the precision-recall curve of 0.4852 means we treat its output only as a shortlist for wet-lab confirmation, never as evidence.
Proposed Experiments
The decisive in vitro comparison is a two-by-three grid: cardiomyocytes carrying wild-type, catalytic-dead, or RNA-binding-dead NAT10 (plus a no-overexpression control), each assayed for cell-autonomous regeneration markers (EdU incorporation, phospho-histone H3, ribosome-protected fragments of Uqcrb) and for paracrine effect on recipient cardiac fibroblasts (scratch closure rate under mitomycin C, N-cadherin levels, and Transwell migration through 3–8 μm pores). The benchmark for a swarming-blocking manipulation is Jiang et al.'s Exherin result — a ~65% reduction in N-cadherin expression that abolished collective swarming — so a secretome effect is only interesting if it reaches a comparable magnitude on N-cadherin or closure kinetics. For context on how weak the unmanipulated system is, adult human cardiomyocyte renewal runs at about 1% per year at age 25, falling to 0.45% by age 75 (Cell cycle arrest of cardiomyocytes in the context of cardiac regeneration), so any proliferation readout is judged against a near-zero baseline.
The decisive in vivo experiment takes the two alleles with the cleanest in vitro separation into cardiomyocyte-specific knock-in mice subjected to myocardial infarction. Endpoints are ejection fraction, scar area, and cardiomyocyte cell-cycle markers, with survival compared against the published reference point for a pro-regenerative intervention in the same injury setting: miR-19a/19b treatment raised post-MI survival from below 50% in controls to roughly 80% (Therapeutic role of miR-19a/19b in cardiac regeneration and protection from myocardial infarction). We will also apply CellChat to single-cell RNA-seq from these hearts to ask whether the predicted communication topology shifts from fibrotic-dominant toward the repair-associated pattern, then confirm the shifted links by protein measurement. No reported result found on Lacuna for absolute LVEF values under Nat10 overexpression or Remodelin in these models, so the in vivo comparison is internally controlled rather than anchored to an external number.
Baselines
The naive reference point is the do-nothing trajectory: untreated cardiomyocyte-fibroblast co-cultures and infarcted mice receiving vehicle, which sets the natural scar-forming baseline. For scale, Jiang et al. report that Engrailed-1-lineage fibroblasts rise from 65.6% of the wounded-fascia population in uninjured tissue to 85.3% in 7-day wounds, a useful calibration for how strongly injury mobilizes the scar-forming lineage even though it comes from fascia rather than heart. The strongest existing competitor is Remodelin dosing, because Xiao et al. showed it preserves ejection fraction and fractional shortening and lowers serum troponin and CK-MB in an LPS model, and Tan et al. showed it halts scratch closure and invasion — making it the method a reviewer would say already achieves anti-inflammatory, anti-migratory cardiac protection with an approved-scaffold-style compound and no genetic engineering. We will run Remodelin head-to-head with the catalytic-dead allele in the same wells, same dose schedule, same assay batches, and same analysis code, so the comparison isolates the one thing Remodelin cannot do by construction: tell us whether the non-catalytic scaffolding function survives. The result that counts as beating Remodelin is catalytic-dead NAT10 matching its anti-inflammatory and anti-migratory effects while also showing EdU incorporation and repressed Uqcrb translation in cardiomyocytes — a combination Remodelin cannot demonstrate, since Ma et al. never tested whether it spares the non-catalytic function. The second competitor is wild-type NAT10 overexpression, the strongest pro-regenerative method in the file: Ma et al. report improved left ventricular ejection fraction, reduced scar area, and elevated Ki67, pH3, and EdU with adult cardiomyocyte-specific overexpression, though no reported result found on Lacuna for the exact fold-changes. Beating it means achieving equal or better cell-cycle re-entry with a lower pro-inflammatory secretome output in the macrophage-contact assays, since wild-type NAT10 in an inflamed environment should feed the ac4C-Ets2 axis that Xiao et al. implicated in cardiac injury. The key ablation is the RNA-binding-dead allele, which isolates the proposal's central ingredient: if the paracrine anti-fibrotic effect tracks the RNA-binding mutant status rather than the catalytic-dead status, the scaffolding function — not loss of catalysis — carries the effect.
Why not just…?
Why not just knock NAT10 out with CRISPR or shRNA? Because a total knockout collapses both jobs at once and cannot attribute any phenotype to either. The literature this proposal builds on is explicit that this ambiguity is fatal: total knockdown of hexokinase 2 destroys glycolysis and masks the nuclear scaffolding role (The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness), and total knockdown of UCK2 conflates nucleotide metabolism with metastatic scaffolding until catalytically dead mutants separated them (The Metabolic and Non-Metabolic Roles of UCK2 in Tumor Progression). For NAT10 specifically, knocking it out in cardiomyocytes removes the very scaffolding function that promotes regeneration, so a knockout experiment would misattribute the loss.
Why not just dose everything with Remodelin? This is the most serious alternative, and we do not argue around it — we test it as a head-to-head baseline. The honest concern is that Remodelin binds the catalytic pocket and could, through the allosteric or steric effects typical of active-site inhibitors, also perturb the adjacent RNA-binding surfaces, in which case the drug would quietly block regeneration while protecting against inflammation. Nothing in the file measures this; Xiao et al. tested Remodelin only in macrophages and endotoxemia, never against cardiomyocyte cell-cycle re-entry. If Remodelin in our grid matches catalytic-dead NAT10 on every readout, including preserved EdU incorporation and Uqcrb repression, then the drug wins and the genetic approach is unnecessary — and the proposal will say so.
Why not just run fibroblast monoculture scratch assays? Because the question is not whether fibroblasts can migrate but what cardiomyocytes tell them to do. Cardiomyocytes Deficiency of SENP1 Promotes Myocardial Fibrosis via Paracrine Action is the direct precedent: a change made entirely inside cardiomyocytes reshaped their secretome and thereby drove fibroblast activation and fibrosis, a result a monoculture would have been completely blind to. We still run monoculture arms as an ablation, so we can say how much of the effect is fibroblast-intrinsic.
Why not just run CellChat on existing single-cell data and skip the wet lab? Because the mechanism under study is precisely one that transcriptomics cannot see. Ma et al. found Uqcr11 and Uqcrb repressed at the level of ribosome-protected fragments without matching changes in steady-state mRNA, and CellChat's own authors note their inference rests on mRNA abundance as a proxy. We use CellChat as a triage tool with a defined precision cost (its false-positive reduction of roughly 10–14% is relative to even noisier single-pair methods), and every predicted link that matters to the claim gets validated by protein measurement in conditioned media.
Why not just reprogram scar fibroblasts into cardiomyocytes with transcription factors? Direct reprogramming with factors like Gata4, Hand2, Mef2c, and Tbx5, discussed in Cardiac cell type-specific responses to injury and contributions to heart regeneration, aims at the same end state by a different route, but it suffers low in vivo conversion efficiency and creates immature, potentially arrhythmogenic cells. Our route forces cell-cycle re-entry of myocytes that are already fully differentiated and electrically integrated, which is exactly the property reprogramming lacks. The two are complementary rather than competing, and a head-to-head is out of scope here.
Decisive Checks
Three results would falsify or settle the claim. First, if catalytic-dead NAT10 fails to repress Uqcrb translation, the decoupling premise inherited from Ma et al. does not survive independent alleles, and the program stops at module one. Second, if the conditioned-media effect on fibroblast swarming is small relative to the Exherin benchmark of ~65% N-cadherin reduction, then cardiomyocyte metabolic state is not a meaningful dial for scar formation, and the paracrine hypothesis dies even if the cell-autonomous regeneration result holds. Third, if Remodelin and catalytic-dead NAT10 are indistinguishable on every cardiomyocyte and fibroblast readout, the simpler pharmacological route suffices and the point mutants become a mechanism-confirming footnote rather than a therapeutic path. Any of these outcomes is a publishable, clean answer to a question two independent papers have left standing in direct tension with each other.
References
- N-Acetyltransferase 10 represses Uqcr11 and Uqcrb independently of ac4C modification to promote heart regeneration
- Impact of N-acetyltransferase 10 on macrophage activation and inflammation-induced cardiac dysfunction
- Injury triggers fascia fibroblast collective cell migration to drive scar formation through N-cadherin
- The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness
- The Metabolic and Non-Metabolic Roles of UCK2 in Tumor Progression
- NAT10 inhibits ferroptosis and promotes the progression of renal clear cell carcinoma by regulating the NFE2L1-GPX4 signaling pathway
- Inference and analysis of cell-cell communication using CellChat
- PACES: prediction of N4-acetylcytidine (ac4C) modification sites in mRNA
- Cell cycle arrest of cardiomyocytes in the context of cardiac regeneration
- Therapeutic role of miR-19a/19b in cardiac regeneration and protection from myocardial infarction
- Cardiomyocytes Deficiency of SENP1 Promotes Myocardial Fibrosis via Paracrine Action
- Cardiac cell type-specific responses to injury and contributions to heart regeneration